{"entity": "journal", "iuid": "cae5f23ad55a422aa93b524be1fbff8e", "timestamp": "2026-09-26T23:03:38.190Z", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/journal/Clin%20Med%20Insights%20Cardiol.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/journal/Clin%20Med%20Insights%20Cardiol"}}, "title": "Clin Med Insights Cardiol", "issn": "1179-5468", "issn-l": null, "publications_count": 1, "publications": [{"entity": "publication", "iuid": "a530fe5909094abab9d0038b6cb5ffbd", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/a530fe5909094abab9d0038b6cb5ffbd.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/a530fe5909094abab9d0038b6cb5ffbd"}}, "title": "Fusidic Acid: A Neglected Risk Factor for Statin-Associated Myopathy.", "authors": [{"family": "R\u00f6nnqvist", "given": "Josefine", "initials": "J"}, {"family": "Hallberg", "given": "P\u00e4r", "initials": "P"}, {"family": "Yue", "given": "Qun-Ying", "initials": "QY"}, {"family": "Wadelius", "given": "Mia", "initials": "M"}], "type": "journal article", "published": "2018-12-04", "journal": {"title": "Clin Med Insights Cardiol", "issn": "1179-5468", "volume": "12", "pages": "1179546818815162", "issn-l": null}, "abstract": "Statins are widely used lipid-lowering drugs used for the prevention of cardiovascular disease. Statins are known to cause myopathy, an adverse drug reaction with various clinical features rhabdomyolysis.\n\nTo describe clinical characteristics of statin-treated individuals who experienced myopathy and identify risk factors of statin-associated myopathy.\n\nA retrospective study was conducted on cases of statin-associated myopathy reported to the Swedish Medical Products Agency. Clinical factors were compared between cases and statin-treated controls not diagnosed with myopathy. Statistical methods were univariate and multivariate logistic regression and results were presented as odds ratio (OR) with 95% confidence interval (CI). To correct for multiple comparisons, the cutoff for statistical significance was set to P < .0017.\n\nIn total, 47 cases of statin-associated myopathy were compared with 3871 treated controls. Rhabdomyolysis was diagnosed in 51% of the cases. Markers for cardiovascular disease were more common in cases than controls. Statistical analysis revealed the following independent risk factors for myopathy: high statin dose (OR = 1.54, calculated using the standard deviation 19.82, 95% CI = 1.32-1.80, P < .0001), and concomitant treatment with fusidic acid (OR = 1002, 95% CI = 54.55-18 410, P < .0001), cyclosporine (OR = 34.10, 95% CI = 4.43-262.45, P = .0007), and gemfibrozil (OR = 12.35, 95% CI = 2.38-64.10, P = .0028).\n\nThe risk of myopathy increases with statin dose and cotreatment with cyclosporine and gemfibrozil. Concomitant fusidic acid has previously only been noted in a few case reports. Considering that use of fusidic acid may become more frequent, it is important to remind of this risk factor for statin-associated myopathy.", "doi": "10.1177/1179546818815162", "pmid": "30618488", "labels": [], "xrefs": [{"db": "pmc", "key": "PMC6299330"}, {"db": "pii", "key": "10.1177_1179546818815162"}], "notes": [], "created": "2026-09-23T12:17:05.885Z", "modified": "2026-09-23T12:17:05.929Z"}], "created": "2026-09-23T12:17:05.893Z", "modified": "2026-09-23T12:17:05.893Z"}